{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T07:54:00Z","timestamp":1787126040701,"version":"build-2736575974"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.suronc.2019.09.006","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T11:27:11Z","timestamp":1568374031000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review"],"prefix":"10.1016","volume":"31","author":[{"given":"Eduardo E.","family":"Montalvo-Jave","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir A.","family":"Rahnemai- Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Papaconstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Espejel","family":"Deloiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamantis I.","family":"Tsilimigras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Moris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German Eduardo","family":"Mendoza-Barrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M.","family":"Pawlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.suronc.2019.09.006_bib1","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","volume":"36","author":"Bridgewater","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ.B."},{"key":"10.1016\/j.suronc.2019.09.006_bib2","series-title":"Biliary Tract Cancer Incidence and Trends in the United States by Demographic Group","first-page":"1999","author":"Van Dyke","year":"2019"},{"key":"10.1016\/j.suronc.2019.09.006_bib3","first-page":"99","article-title":"Gallbladder cancer: epidemiology and outcome","volume":"6","author":"Hundal","year":"2014","journal-title":"Clin. Epidemiol."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5009\/gnl.2012.6.2.172","article-title":"Epidemiology of gallbladder disease: cholelithiasis and cancer","volume":"6","author":"Stinton","year":"2012","journal-title":"Gut Liver"},{"key":"10.1016\/j.suronc.2019.09.006_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/967472","article-title":"Gallbladder cancer in the 21st century","volume":"2015","author":"Kanthan","year":"2015","journal-title":"J. Oncol."},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib6","first-page":"563","article-title":"Epidemiology, incidence, and mortality of gallbladder cancer and its relation with development in the world","volume":"10","author":"Mahdavifar","year":"2017","journal-title":"Ann. Trop. Med. Public Health"},{"issue":"7","key":"10.1016\/j.suronc.2019.09.006_bib7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/ijc.21683","article-title":"Gallbladder cancer worldwide: geographical distribution and risk factors","volume":"118","author":"Randi","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib8","first-page":"1","article-title":"Gallbladder carcinoma in the United States: a population based clinical outcomes study involving 22,343 patients from the surveillance, epidemiology, and end result database (1973-2013)","volume":"2017","author":"Lau","year":"2017","journal-title":"HPB Surg.\u202f: World J. Hepatic, Pancreatic Biliary Surg."},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib9","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/cam4.1044","article-title":"Trend analysis and survival of primary gallbladder cancer in the United States: a 1973-2009 population-based study","volume":"6","author":"Rahman","year":"2017","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.suronc.2019.09.006_bib10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jso.21141","article-title":"Gallbladder cancer (GBC): 10-year experience at memorial sloan-kettering cancer centre (MSKCC)","volume":"98","author":"Duffy","year":"2008","journal-title":"J. Surg. Oncol."},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib11","article-title":"Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study","volume":"13","author":"Samuel","year":"2018"},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib12","first-page":"1922","article-title":"Neuroendocrine carcinomas of the gallbladder: lessons learnt from cases at opposite ends of the spectrum","volume":"23","author":"Moris","year":"2018","journal-title":"J BUON"},{"issue":"7","key":"10.1016\/j.suronc.2019.09.006_bib13","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ijc.27777","article-title":"Risk factors for gallbladder cancer: a case-control study","volume":"132","author":"Jain","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1067\/msy.2001.113888","article-title":"Carcinoma in the porcelain gallbladder: a relationship revisited","volume":"129","author":"Stephen","year":"2001","journal-title":"Surgery"},{"issue":"15","key":"10.1016\/j.suronc.2019.09.006_bib15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jnci\/89.15.1132","article-title":"Epidemiologic aspects of gallbladder cancer: a case-control study of the SEARCH program of the international agency for research on cancer","volume":"89","author":"Zatonski","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"issue":"8889","key":"10.1016\/j.suronc.2019.09.006_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0140-6736(94)90816-8","article-title":"Cancer mortality in chronic typhoid and paratyphoid carriers","volume":"343","author":"Caygill","year":"1994","journal-title":"Lancet (London, England)"},{"issue":"9","key":"10.1016\/j.suronc.2019.09.006_bib17","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/sj.bjc.6603703","article-title":"Obesity and the risk of gallbladder cancer: a meta-analysis","volume":"96","author":"Larsson","year":"2007","journal-title":"Br. J. Canc."},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib18","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00000658-200010000-00011","article-title":"Gallbladder cancer: comparison of patients presenting initially for definitive operation with those presenting after prior noncurative intervention","volume":"232","author":"Fong","year":"2000","journal-title":"Ann. Surg."},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/01.sla.0000154118.07704.ef","article-title":"An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center","volume":"241","author":"Dixon","year":"2005","journal-title":"Ann. Surg."},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s12029-017-9940-y","article-title":"Patterns of presentation, treatment, and survival rates of gallbladder cancer: a prospective study at a tertiary care centre","volume":"49","author":"Singh","year":"2018","journal-title":"J. Gastrointest. Cancer"},{"issue":"8","key":"10.1016\/j.suronc.2019.09.006_bib21","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/jso.25450","article-title":"The optimal number of lymph nodes to evaluate among patients undergoing surgery for gallbladder cancer: correlating the number of nodes removed with survival in 6531 patients","volume":"119","author":"Tsilimigras","year":"2019","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13193-015-0443-7","article-title":"Chemotherapy compared with best supportive care for metastatic\/unresectable gallbladder cancer: a non-randomized prospective cohort study","volume":"7","author":"Singh","year":"2016","journal-title":"Indian J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cam4.975","article-title":"Does radiotherapy still have a role in unresected biliary tract cancer?","volume":"6","author":"Pollom","year":"2016","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.suronc.2019.09.006_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/1097-0142(19800301)45:5<919::AID-CNCR2820450514>3.0.CO;2-4","article-title":"The precursor lesions of invasive gallbladder carcinoma. Hyperplasia, atypical hyperplasia and carcinoma in situ","volume":"45","author":"Albores-Saavedra","year":"1980","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0344-0338(83)80085-5","article-title":"Histogenesis of epithelial neoplasms of human gallbladder I. Dysplasia","volume":"178","author":"Laitio","year":"1983","journal-title":"Pathol. Res. Pract."},{"issue":"8","key":"10.1016\/j.suronc.2019.09.006_bib26","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1002\/1097-0142(19861015)58:8<1702::AID-CNCR2820580821>3.0.CO;2-Z","article-title":"The histogenesis of adenocarcinoma of the gallbladder","volume":"58","author":"Dowling","year":"1986","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0046-8177(86)80134-4","article-title":"Intestinal metaplasia of the gallbladder: a morphologic and immunocytochemical study","volume":"17","author":"Albores-Saavedra","year":"1986","journal-title":"Hum. Pathol."},{"issue":"10","key":"10.1016\/j.suronc.2019.09.006_bib28","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/1097-0142(19821115)50:10<2226::AID-CNCR2820501043>3.0.CO;2-3","article-title":"Relation of adenoma to carcinoma in the gallbladder","volume":"50","author":"Kozuka","year":"1982","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.suronc.2019.09.006_bib29","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jso.20527","article-title":"Preneoplastic lesions in gallbladder cancer","volume":"93","author":"Roa","year":"2006","journal-title":"J. Surg. Oncol."},{"issue":"Suppl 4","key":"10.1016\/j.suronc.2019.09.006_bib30","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/annonc\/10.suppl_4.S136","article-title":"Histological and genetic changes in malignant transformation of gallbladder adenoma","volume":"10","author":"Watanabe","year":"1999","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2559.2008.03192.x","article-title":"Gallbladder cancer: a morphological and molecular update","volume":"55","author":"Goldin","year":"2009","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib32","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdu006","article-title":"A genetic model for gallbladder carcinogenesis and its dissemination","volume":"25","author":"Barreto","year":"2014","journal-title":"Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol."},{"issue":"8","key":"10.1016\/j.suronc.2019.09.006_bib33","first-page":"763","article-title":"Loss of heterozygosity in dysplasia and carcinoma of the gallbladder, Modern pathology : an","volume":"12","author":"Chang","year":"1999","journal-title":"Off. J. United States Can. Acad. Pathol. Inc"},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0304-3835(01)00562-6","article-title":"Genetic alterations in gallbladder adenoma, dysplasia and carcinoma","volume":"169","author":"Kim","year":"2001","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/sj.bjc.6600490","article-title":"High resolution chromosome 3p, 8p, 9q and 22q allelotyping analysis in the pathogenesis of gallbladder carcinoma","volume":"87","author":"Wistuba","year":"2002","journal-title":"Br. J. Canc."},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/SLA.0000000000000495","article-title":"Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer","volume":"260","author":"Jain","year":"2014","journal-title":"Ann. Surg."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0304-3835(03)00385-9","article-title":"Expression of Fhit, Mlh1, and P53 protein in human gallbladder carcinoma","volume":"199","author":"Koda","year":"2003","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib38","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0002-9440(10)61157-1","article-title":"Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma","volume":"160","author":"Wistuba","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib39","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1055-3207(02)00042-X","article-title":"Cellular and molecular biology of biliary tract cancers","volume":"11","author":"Rashid","year":"2002","journal-title":"Surg. Oncol. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s005340050176","article-title":"Relation between K-ras codon 12 mutation and p53 protein overexpression in gallbladder cancer and biliary ductal epithelia in patients with pancreaticobiliary maljunction","volume":"7","author":"Masuhara","year":"2000","journal-title":"J. Hepatobiliary Pancreat. Surg."},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib41","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S1072-7515(01)01012-2","article-title":"Association of p53, p16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer","volume":"193","author":"Quan","year":"2001","journal-title":"J. Am. Coll. Surg."},{"issue":"21","key":"10.1016\/j.suronc.2019.09.006_bib42","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.3748\/wjg.v12.i21.3425","article-title":"Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions","volume":"12","author":"Legan","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0046-8177(96)90109-4","article-title":"p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study","volume":"27","author":"Wistuba","year":"1996","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1440-1827.1995.tb03380.x","article-title":"p53 immunostaining distinguishes malignant from benign lesions of the gall-bladder","volume":"45","author":"Oohashi","year":"1995","journal-title":"Pathol. Int."},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib45","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13651820410025110","article-title":"Gallbladder carcinoma: the role of p53 protein overexpression and Ki-67 antigen expression as prognostic markers","volume":"6","author":"Hidalgo Grau","year":"2004","journal-title":"HPB : Off. J. Int. Hepato Pancreato Biliary Assoc."},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/path.1711700111","article-title":"p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder","volume":"170","author":"Kamel","year":"1993","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.suronc.2019.09.006_bib47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/jcp.47.5.453","article-title":"Clinical importance of p53 protein in gall bladder carcinoma and its precursor lesions","volume":"47","author":"Wee","year":"1994","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.suronc.2019.09.006_bib48","first-page":"527","article-title":"Cyclooxygenase expression in the gallbladder","volume":"6","author":"Ghosh","year":"2000","journal-title":"Int. J. Mol. Med."},{"issue":"10","key":"10.1016\/j.suronc.2019.09.006_bib49","first-page":"4096","article-title":"Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas","volume":"6","author":"Shi","year":"2000","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib50","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.yexmp.2011.06.004","article-title":"The risk factor of gallbladder cancer: hyperplasia of mucous epithelium caused by gallstones associates with p16\/CyclinD1\/CDK4 pathway","volume":"91","author":"Feng","year":"2011","journal-title":"Exp. Mol. Pathol."},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib51","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.anndiagpath.2007.06.003","article-title":"Expression of the p16(INK4a) gene product in premalignant and malignant epithelial lesions of the gallbladder","volume":"12","author":"Lynch","year":"2008","journal-title":"Ann. Diagn. Pathol."},{"issue":"36","key":"10.1016\/j.suronc.2019.09.006_bib52","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3748\/wjg.15.4511","article-title":"EGFR and HER2 expression in advanced biliary tract cancer","volume":"15","author":"Harder","year":"2009","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.suronc.2019.09.006_bib53","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0344-0338(11)80652-7","article-title":"Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours","volume":"191","author":"Lee","year":"1995","journal-title":"Pathol. Res. Pract."},{"issue":"5","key":"10.1016\/j.suronc.2019.09.006_bib54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7150\/ijms.5.285","article-title":"EGFR expression in gallbladder carcinoma in North America","volume":"5","author":"Kaufman","year":"2008","journal-title":"Int. J. Med. Sci."},{"issue":"5","key":"10.1016\/j.suronc.2019.09.006_bib55","first-page":"1127","article-title":"Expression of the c-erb-B2 and p53 protein in gallbladder carcinomas","volume":"8","author":"Kim","year":"2001","journal-title":"Oncol. Rep."},{"issue":"11","key":"10.1016\/j.suronc.2019.09.006_bib56","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0344-0338(11)80652-7","article-title":"Epidermal growth factor receptor immunoreactivity in gallbladder and extrahepatic biliary tract tumours","volume":"191","author":"Lee","year":"1995","journal-title":"Pathol. Res. Pract."},{"issue":"7","key":"10.1016\/j.suronc.2019.09.006_bib57","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00423-013-1104-3","article-title":"Staging laparoscopy for hilar cholangiocarcinoma in 100 patients","volume":"398","author":"Barlow","year":"2013","journal-title":"Langenbeck's Arch. Surg."},{"issue":"8","key":"10.1016\/j.suronc.2019.09.006_bib58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jso.20534","article-title":"CA 125: a potential tumor marker for gallbladder cancer","volume":"93","author":"Chaube","year":"2006","journal-title":"J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib59","first-page":"160","article-title":"Diagnostic value of serum CA242, CA 19-9, CA 15-3 and CA 125 in patients with carcinoma of the gallbladder","volume":"27","author":"Shukla","year":"2006","journal-title":"Trop. Gastroenterol. : Off. J. Dig. Dis. Found."},{"issue":"14","key":"10.1016\/j.suronc.2019.09.006_bib60","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.3748\/wjg.v20.i14.4085","article-title":"Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib61","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12029-011-9288-7","article-title":"Evaluation of CA 242 as a tumor marker in gallbladder cancer","volume":"43","author":"Rana","year":"2012","journal-title":"J. Gastrointest. Cancer"},{"issue":"16","key":"10.1016\/j.suronc.2019.09.006_bib62","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3760\/cma.j.issn.0366-6999.20120341","article-title":"Tumor biomarkers: help or mislead in the diagnosis of xanthogranulomatous cholecystitis?-analysis of serum CA 19-9, carcinoembryonic antigen, and CA 12-5","volume":"126","author":"Yu","year":"2013","journal-title":"Chin. Med. J."},{"issue":"7","key":"10.1016\/j.suronc.2019.09.006_bib63","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.20469","article-title":"Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma","volume":"101","author":"Koopmann","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib64","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s005350050112","article-title":"Intrahepatic cholangiocarcinoma with increased serum CYFRA 21-1 level","volume":"33","author":"Kashihara","year":"1998","journal-title":"J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0973-6883(11)60110-2","article-title":"Circulating CYFRA 21-1 is a specific diagnostic and prognostic biomarker in biliary tract cancer","volume":"1","author":"Chapman","year":"2011","journal-title":"J. Clin. Exper. Hepatol."},{"issue":"11","key":"10.1016\/j.suronc.2019.09.006_bib66","first-page":"6663","article-title":"Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study","volume":"34","author":"Lumachi","year":"2014","journal-title":"Anticancer Res."},{"issue":"5","key":"10.1016\/j.suronc.2019.09.006_bib67","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s10620-014-3472-0","article-title":"Serum CYFRA 21-1 in biliary tract cancers: a reliable biomarker for gallbladder carcinoma and intrahepatic cholangiocarcinoma","volume":"60","author":"Huang","year":"2015","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.suronc.2019.09.006_bib68","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12032-014-0167-5","article-title":"Expression of serum survivin protein in diagnosis and prognosis of gallbladder cancer: a comparative study","volume":"31","author":"Nigam","year":"2014","journal-title":"Med. Oncol. (Northwood, London, England)"},{"issue":"9","key":"10.1016\/j.suronc.2019.09.006_bib69","doi-asserted-by":"crossref","first-page":"9241","DOI":"10.1007\/s13277-014-2200-x","article-title":"Expression of survivin mRNA in gallbladder cancer: a diagnostic and prognostic marker?","volume":"35","author":"Nigam","year":"2014","journal-title":"Tumour Biol. : J. Int. Soc. Oncodevelopmental Biol. Med."},{"key":"10.1016\/j.suronc.2019.09.006_bib70","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918794630","article-title":"Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology","volume":"10","author":"Palmirotta","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib71","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12253-016-0087-0","article-title":"Quantification of circulating free DNA as a diagnostic marker in gall bladder cancer","volume":"23","author":"Kumari","year":"2017","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.suronc.2019.09.006_bib72","series-title":"Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma, Pathology Oncology Research","author":"Kumari","year":"2018"},{"issue":"12","key":"10.1016\/j.suronc.2019.09.006_bib73","first-page":"3429","article-title":"EpCAM-based flow cytometric detection of circulating tumor cells in gallbladder carcinoma cases","volume":"18","author":"Awasthi","year":"2017","journal-title":"Asian Pac. J. Cancer Prev. APJCP : Asian Pac. J. Cancer Prev. APJCP"},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3892\/mco.2016.905","article-title":"The role of microRNAs in gallbladder cancer","volume":"5","author":"Yang","year":"2016","journal-title":"Mol. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.suronc.2019.09.006_bib75","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.hpb.2017.06.011","article-title":"Elevation of CA19-9 and CEA is associated with a poor prognosis in patients with resectable gallbladder carcinoma","volume":"19","author":"Wen","year":"2017","journal-title":"HPB (Oxford)"},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib76","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/s41598-018-38396-4","article-title":"Preoperative platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as predictors of clinical outcome in patients with gallbladder cancer","volume":"9","author":"Zhu","year":"2019","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.suronc.2019.09.006_bib77","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s12094-015-1310-2","article-title":"Prognostic significance of preoperative neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio in patients with gallbladder carcinoma","volume":"17","author":"Zhang","year":"2015","journal-title":"Clin. Transl. Oncol."},{"issue":"7","key":"10.1016\/j.suronc.2019.09.006_bib78","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/PAI.0b013e3182a318a9","article-title":"Immunohistochemical expression of vascular endothelial growth factor A in advanced gallbladder carcinoma","volume":"22","author":"Letelier","year":"2014","journal-title":"Appl. Immunohistochem. Mol. Morphol. : Appl. Immunohistochem. Mol. Morphol. AIMM"},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib79","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3748\/wjg.v21.i4.1243","article-title":"Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma","volume":"21","author":"Zhang","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"28","key":"10.1016\/j.suronc.2019.09.006_bib80","doi-asserted-by":"crossref","first-page":"9564","DOI":"10.3748\/wjg.v20.i28.9564","article-title":"Prognostic significance of nuclear hepatoma-derived growth factor expression in gallbladder cancer","volume":"20","author":"Tao","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib81","first-page":"42","article-title":"Overexpression of the HER2\/neu gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest. Cancer Res. : GCR"},{"issue":"8","key":"10.1016\/j.suronc.2019.09.006_bib82","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/apm.12551","article-title":"The prognostic significance of survivin expression in gallbladder carcinoma","volume":"124","author":"Salman","year":"2016","journal-title":"APMIS: Acta Pathol. Microbiol. Immunol. Scand."},{"issue":"8","key":"10.1016\/j.suronc.2019.09.006_bib83","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.prp.2011.05.010","article-title":"Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma","volume":"207","author":"Liu","year":"2011","journal-title":"Pathol. Res. Pract."},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib84","first-page":"667","article-title":"Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma","volume":"100","author":"Wang","year":"2014","journal-title":"Tumori"},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib85","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-014-0276-y","article-title":"SPOCK1 as a potential cancer prognostic marker promotes the proliferation and metastasis of gallbladder cancer cells by activating the PI3K\/AKT pathway","volume":"14","author":"Shu","year":"2015","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.suronc.2019.09.006_bib86","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3892\/ol.2014.1886","article-title":"TSG101 and PEG10 are prognostic markers in squamous cell\/adenosquamous carcinomas and adenocarcinoma of the gallbladder","volume":"7","author":"Liu","year":"2014","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib87","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12094-013-1063-8","article-title":"PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer","volume":"16","author":"Li","year":"2014","journal-title":"Clin. Transl. Oncol.: Off. Publ. Feder. Span. Oncol. Soc. Natl. Cancer Inst. Mex."},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib88","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/07357907.2016.1193745","article-title":"SHP2 and UGP2 are biomarkers for progression and poor prognosis of gallbladder cancer","volume":"34","author":"Wang","year":"2016","journal-title":"Canc. Invest."},{"key":"10.1016\/j.suronc.2019.09.006_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/cddiscovery.2017.69","article-title":"Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks","volume":"3","author":"Xu","year":"2017","journal-title":"Cell Death Discov."},{"issue":"6","key":"10.1016\/j.suronc.2019.09.006_bib90","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.prp.2014.01.014","article-title":"N-cadherin and P-cadherin are biomarkers for invasion, metastasis, and poor prognosis of gallbladder carcinomas","volume":"210","author":"Yi","year":"2014","journal-title":"Pathol. Res. Pract."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib91","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1499-3872(13)60030-2","article-title":"Correlation of S1P1 and ERp29 expression to progression, metastasis, and poor prognosis of gallbladder adenocarcinoma","volume":"12","author":"Yuan","year":"2013","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"issue":"9","key":"10.1016\/j.suronc.2019.09.006_bib92","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1158\/1078-0432.CCR-03-0528","article-title":"Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival","volume":"10","author":"Varga","year":"2004","journal-title":"Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res."},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib93","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1309\/H8JEEAEB69J3KYND","article-title":"Expression of epithelial cell adhesion molecule in gallbladder carcinoma and its correlation with clinicopathologic variables","volume":"129","author":"Prince","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.suronc.2019.09.006_bib94","doi-asserted-by":"crossref","DOI":"10.1186\/1746-1596-6-100","article-title":"Expression of MK-1 and RegIV and its clinicopathological significances in the benign and malignant lesions of gallbladder","volume":"6","author":"Yang","year":"2011","journal-title":"Diagn. Pathol."},{"issue":"5","key":"10.1016\/j.suronc.2019.09.006_bib95","first-page":"937","article-title":"Prognostic significance of S100A4 expression in gallbladder cancer","volume":"20","author":"Nakamura","year":"2002","journal-title":"Int. J. Oncol."},{"issue":"12","key":"10.1016\/j.suronc.2019.09.006_bib96","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1054\/bjoc.2001.2192","article-title":"RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer","volume":"85","author":"Oshikiri","year":"2001","journal-title":"Br. J. Canc."},{"issue":"5","key":"10.1016\/j.suronc.2019.09.006_bib97","first-page":"6423","article-title":"Cytoplasmic CD133 expression correlates with histologic differentiation and is a significant prognostic factor in extrahepatic bile duct cancer and gallbladder cancer","volume":"16","author":"Mizukami","year":"2018","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib98","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jhep.2013.04.034","article-title":"MiR-20a triggers metastasis of gallbladder carcinoma","volume":"59","author":"Chang","year":"2013","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.suronc.2019.09.006_bib99","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s13277-013-1207-z","article-title":"miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells","volume":"35","author":"Jin","year":"2014","journal-title":"Tumour Biol. : J. Int. Soc. Oncodevelopmental Biol. Med."},{"issue":"3","key":"10.1016\/j.suronc.2019.09.006_bib100","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317692249","article-title":"MicroRNA-125b predicts clinical outcome and suppressed tumor proliferation and migration in human gallbladder cancer","volume":"39","author":"Yang","year":"2017","journal-title":"Tumor Biol."},{"issue":"1","key":"10.1016\/j.suronc.2019.09.006_bib101","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1038\/s41598-019-40857-3","article-title":"Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p","volume":"9","author":"Goeppert","year":"2019","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.suronc.2019.09.006_bib102","first-page":"21241","article-title":"MicroRNA-155 expression as a prognostic factor in patients with gallbladder carcinoma after surgical resection","volume":"8","author":"Zhang","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.suronc.2019.09.006_bib103","first-page":"1625","article-title":"Increased expression of microRNA-335 predicts a favorable prognosis in primary gallbladder carcinoma","volume":"6","author":"Peng","year":"2013","journal-title":"OncoTargets Ther."}],"container-title":["Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740419302828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960740419302828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T03:17:00Z","timestamp":1760757420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960740419302828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":103,"alternative-id":["S0960740419302828"],"URL":"https:\/\/doi.org\/10.1016\/j.suronc.2019.09.006","relation":{},"ISSN":["0960-7404"],"issn-type":[{"value":"0960-7404","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular pathways and potential biomarkers in gallbladder cancer: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.suronc.2019.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}